ClinicalTrials.gg
CompletedNCT07379879ANCCRUpdated Feb 2, 2026

Acute Neurochemical and Cognitive Changes After HIIT vs MICT/LICT

An interventional study of Low Intensity Exercise and Moderate-Intensity Continuous Exercise in BDNF, Cognitive Performance and Lactate, sponsored by Aksaray University Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Aksaray University Training and Research Hospital · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2025, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
Male
01

Study summary

This study examines whether the intensity of a single running session changes a blood marker related to brain health (brain-derived neurotrophic factor, BDNF), blood lactate, and performance on a short thinking task that measures attention and self-control (the Stroop test) in healthy young adult men.

Twelve healthy males (18-25 years) will complete four separate sessions in a randomized, counterbalanced order, with at least 7 days between sessions. Each session includes an 8-minute warm-up followed by 24 minutes of one of the following conditions: low-intensity continuous running, moderate-intensity continuous running, high-intensity interval running (repeated 15-second fast runs with 15-second passive rest, organized into sets), or a seated rest control session. Running pace will be individualized based on a prior fitness test.

A small venous blood sample (about 8 mL) will be collected immediately before and within 1 minute after each session. After each session, participants will complete the Stroop test. The main outcomes are the before-to-after changes in serum BDNF, blood lactate, and Stroop test performance across the four conditions.

02

Conditions studied

  • BDNF
  • Cognitive Performance
  • Lactate
  • Exercise Intensity

Keywords

  • BDNF
  • Cognitive Performance
  • Stroop Test
03

In context

Lead sponsor

Aksaray University Training and Research Hospital is the lead sponsor of 25 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 25 years
  • No known medical condition that prevents participation in exercise
  • Not currently using any pharmacological agents

Exclusion criteria

Exclusion Criteria:

  • Experiencing any discomfort before, during, or after exercise
  • Current or past diagnosis of pharmacological or doping substance use
  • Engaging in regular exercise (more than 3 times per week) within the last 2 weeks
  • History of alcohol or substance addiction
  • Any other condition or factor that may prevent full participation in the study protocol
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
12 participants (actual)

Study arms

  • No intervention
    Control

    Participants remained seated quietly at rest for 24 minutes in a quiet, well-lit room, matched to the exercise sessions for time schedule and environmental conditions. No physical activity was performed during this period.

  • Experimental
    Low-intensity continuous training

    They were asked to perform low intensity exercise for the specified time, determined according to their maximal oxygen consumption capacity.

    Behavioral: Low Intensity Exercise

  • Experimental
    Moderate-intensity continuous training

    They were asked to perform moderate intensity exercise for the specified time, determined according to their maximal oxygen consumption capacity.

    Behavioral: Moderate-Intensity Continuous Exercise

  • Experimental
    High-intensity interval training

    They were asked to perform HIIT exercise for the specified time, determined according to their maximal oxygen consumption capacity.

    Behavioral: High-Intensity Interval Training

Interventions

  • BehavioralLow Intensity Exercise

    Participants ran continuously for 24 minutes at 50-60% of their MAS without rest

  • BehavioralModerate-Intensity Continuous Exercise

    Participants completed a continuous 24-min running bout at 70-80% of their MAS. The exercise was performed at a steady, uninterrupted pace throughout the session, with no planned rest periods. Participants were instructed to maintain the prescribed pace for the entire duration

  • BehavioralHigh-Intensity Interval Training

    Participants performed 15-s running bouts at 110-120% of MAS, with the target distance for each bout pre-calculated from individual MAS (speed × time). Running was conducted shuttle-style between two cones. At the whistle, participants ran from one cone to the other for 15 s and then remained standing still for a 15-s passive rest at that cone. At the next whistle, they ran back in the opposite direction, followed by another 15-s stationary recovery. This 15-s run/15-s recovery cycle continued for 3 min, constituting one set (6 runs and 6 recovery intervals per set). Four sets were completed, separated by 3-min passive inter-set rest, resulting in a total session duration of 24 min

06

What researchers measure

Primary outcomes

  1. Lactate

    Lactate levels were measured in millimoles per liter (mmol/L) from capillary/venous blood samples taken before and after exercise using a lactate analyzer.

    Time frame: Baseline, Immediately After Exercise (Day 1)

  2. BDNF

    BDNF levels were measured using a Sunred brand ELISA kit from blood samples taken baseline and after exercise, and the results were reported in ng/mL units.

    Time frame: Baseline, Immediately After Exercise (Day 1)

  3. Stroop Test

    Stroop test performance will be assessed as an indicator of executive function, primarily selective attention and inhibitory control. In this task, participants are required to identify the ink color of presented stimuli while suppressing the automatic tendency to read the written word, particularly during incongruent trials (e.g., the word "red" printed in blue ink). The test will be administered immediately after each session. Outcomes will include reaction time and accuracy (and/or an interference score derived from incongruent vs. congruent conditions). Reaction time will be recorded in seconds (s), with poorer performance reflected by slower responses and/or more errors.

    Time frame: Baseline and immediately after exercise (Day 1)

07

Study locations

1 site
  • Aksaray University
    Aksaray, Center 68000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided — A key risk is participant re-identification due to the small sample size and the presence of biomarker and performance data that could enable triangulation, even after de-identification.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Sep 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2026
First posted
Feb 2, 2026
StartActual
Aug 1, 2025
Primary completionActual
Sep 20, 2025
CompletionActual
Sep 25, 2025
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07379879
Lead sponsor
Aksaray University Training and Research Hospital
Responsible party
serkan pancar (Assoc. Prof., Aksaray University Training and Research Hospital) — Principal investigator
First posted
Feb 2, 2026
Start date
Aug 1, 2025
Primary completion
Sep 20, 2025
Completion
Sep 25, 2025
Last update
Feb 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion